Senior Clinical Investigator Fellowship (SCIF/FKM)

Didier EBO
Content

- Aim
- Personal SCIF (and extension)
- Pros and cons
A Senior Clinical Investigator fellowship aims at well-trained medical researchers of postdoctoral level who must be able to establish a career and offer them the chance to obtain part-time leave from a clinical position in order to work on a translational research project.

Translational research bridges the gap between fundamental biomedical research and clinical research that focusses on the patient.
Personal SCIF (& extension)

- Fundamental: mechanisms governing activation & inhibition of human basophils (inc. signalling)

- Translational: development and validation of BAT/HistaFlow® (drug allergy: lack other diagnostics)

- Clinical: set-up of care pathway in drug allergy diagnosis (reference center: antibiotics, anesthetics)

- “Spin-off”: HistaFlow® patent
Personal SCIF (& extension)

- Fundamental: mechanisms governing activation & inhibition of human basophils (inc. signalling)

- Translational: development and validation of BAT/HistaFlow® (drug allergy: lack other diagnostics)

- Clinical: set-up of care pathway in drug allergy diagnosis (reference center: antibiotics, anesthetics)

- “Spin-off”: HistaFlow® patent
Combined analysis of intracellular signalling and immunophenotype of human peripheral blood basophils by flow cytometry: a proof of concept

Department of Immunology, Allergology, Rheumatology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium

Original Article

STAT5 in Human Basophils: IL-3 Is Required for Its FceRI-Mediated Phosphorylation

Marjoke M. Verweij, Vito Sabato, Sara Nullens, Chris H. Bridts, Luc S. De Clerck, Wim J. Stevens, and Didier G. Ebo*
Department of Immunology—Allergology—Rheumatology, Faculty of Medicine, University of Antwerp, Belgium


Original Articles

Simultaneous Flow Cytometric Detection of Basophil Activation Marker CD63 and Intracellular Phosphorylated p38 Mitogen-Activated Protein Kinase in Birch Pollen Allergy

Nicolaas E. Aerts,1 Evelyne J. Dombrecht,1 Chris H. Bridts,1 Margo M. Hagendorens,1,2 Luc S. de Clerck,1,3* Wim J. Stevens,1,3 and Didier G. Ebo1,3*
1Department of Immunology—Allergology—Rheumatology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium
2Department of Pediatrics, University of Antwerp Hospital, Antwerp, Belgium
3Department of Immunology—Allergology—Rheumatology, University of Antwerp Hospital, Antwerp, Belgium

Cytometry Part B (Clinical Cytometry) 00:000–000 (2008)
**Original Article**

CD300a is Expressed on Human Basophils and Seems to Inhibit IgE/FcεRI-Dependent Anaphylactic Degranulation

Vito Sabato,1,2 Marjoke M. Verweij,1 Chris H. Bridts,1 Francesca Levi-Schaffer,3 Bernhard F. Gibbs,4 Luc S. De Clerck,1 Domenico Schiavino,2 and Didier G. Ebo1,∗

1Department of Immunology, Allergology, Rheumatology, Faculty of Medicine, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium
2Department of Allergology, Faculty of Medicine, Catholic University of Sacred Heart, Rome, Italy
3Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
4Medway School of Pharmacy, University of Kent, Chatham Maritime, United Kingdom

---

**Letter to the Editor**

Mechanism of phosphatidylserine inhibition of IgE/FcεRI-dependent anaphylactic human basophil degranulation via CD300a

of nonstained liposomes with isolated basophils7 at 37°C for 30 minutes before anti-IgE stimulation. These experiments revealed that only PS-coated liposomes bind basophilic membranes (Fig 1, D) and inhibit IgE/FcεRI-mediated activation of the cells in a

Vito Sabato, MDa,b
Monica Boita, MSc
Saif Shubber, PhD
Chris H. Bridts, MLTa,b
Akira Shibuya, PhD
Luc S. De Clerck, MD, PhDa,b
Franco H. Falcone, PhD
Didier G. Ebo, MD, PhDa,b
Personal SCIF (& extension)

- Fundamental: mechanisms governing activation & inhibition of human basophils (inc. signalling)

- Translational: development and validation of BAT/HistaFlow® (drug allergy: lack other diagnostics)

- Clinical: set-up of care pathway in drug allergy diagnosis (reference center: antibiotics, anesthetics)

- “Spin-off”: HistaFlow® patent
Drug allergy

- 15% drug-related adverse events
- Major cause of anaphylaxis in hospital
- Almost no (validated) in vitro diagnostics available
- Skin tests, drug provocation tests
- No industrial interest
Allergy to rocuronium: from clinical suspicion to correct diagnosis

J. Leysen¹, C. H. Bridts¹, L. S. De Clerck¹, M. Vercauteren², J. Lambert³, J. J. Weyler⁴, W. J. Stevens¹ & D. G. Ebo¹

¹Department of Immunology, University of Antwerp, Antwerp; ²Department of Anaesthesiology, University of Antwerp, Antwerp; ³Department of Dermatology, University of Antwerp, Antwerp; ⁴Department of Epidemiology and Social Medicine, University of Antwerp, Antwerp, Belgium

Flowcytometric diagnosis of atracurium-induced anaphylaxis

A. P. Uyttebroek¹,², V. Sabato¹,², J. Leysen¹,², C. H. Bridts¹,², L. S. De Clerck¹,² & D. G. Ebo¹,²

¹Department of Immunology, Allergology, Rheumatology, Faculty of Medicine and Health Sciences, University of Antwerp; ²Department of Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium

Original Article

IgE-Mediated Allergy to Pholcodine and Cross-Reactivity to Neuromuscular Blocking Agents: Lessons from Flow Cytometry

J. Leysen, L. De Witte, V. Sabato, M. Faber, M. Hagendorens, C. Bridts, L. De Clerck, and D. Ebo*

Faculty of Medicine and Health Science, Department of Immunology, Allergology and Rheumatology, University Antwerp and Antwerp University Hospital, Antwerp, Belgium
Personal SCIF (& extension)

- Fundamental: mechanisms governing activation & inhibition of human basophils (inc. signalling)

- Translational: development and validation of BAT/HistaFlow® (drug allergy: lack other diagnostics)

- Clinical: set-up of care pathway in drug allergy diagnosis (reference center: antibiotics, anesthetics)
  - Over 300 referrals yearly
  - Anesthesia DB: > 600 patients

- “Spin-off”: HistaFlow® patent
Personal SCIF (& extension)

- Fundamental: mechanisms governing activation & inhibition of human basophils (inc. signalling)

- Translational: development and validation of BAT/HistaFlow® (drug allergy: lack other diagnostics)

- Clinical: set-up of care pathway in drug allergy diagnosis (reference center: antibiotics, anesthetics)

- “Spin-off”: HistaFlow® patent
Analyzing histamine release by flow cytometry (HistaFlow): A novel instrument to study the degranulation patterns of basophils

Didier G. Ebo\textsuperscript{a,b,*}, Chris H. Bridts\textsuperscript{a,b}, Christel H. Mertens\textsuperscript{a}, Margo M. Hagendorens\textsuperscript{a,c}, Wim J. Stevens\textsuperscript{a,b}, Luc S. De Clerck\textsuperscript{a,b}

\textsuperscript{a} Immunology–Allergology–Rheumatology, University of Antwerp, Antwerpen, Belgium
\textsuperscript{b} Immunology–Allergology–Rheumatology, Antwerp University Hospital, Edegem (Antwerpen), Belgium
\textsuperscript{c} Pediatrics, University Hospital Antwerp, Antwerpen, Belgium
Pros and cons (difficulties)

- **Pros**
  - Focus: medical researchers
  - Independent from industry (investigator driven)
    - Drug & food allergy
  - Promotership

- **“Cons” & difficulties**
  - No bench fee (other projects)
  - Evaluation of “progress” ~ original project (take into account side ways)
  - “Leave the clinics”: replacement (less expertise)
  - “Uncertainties effect on carreer” (ZAP promotion)
PhD-promotership (#7)

- **J. Leysen**: drug allergy (anesthetics, opiates) (BOF)
- **M. Verweij**: hazelnut sensitization profiles (IWT)
- **V. Sabato**: basophil activation & inhibition (FWO)
- **M. Faber**: food allergy: new sensitizations (BOF)
- **A. Uyttebroek**: drug allergy (BOF)
- **N. Cop**: human mast cell activation (BOF)
- **I. De Cuyper**: Cannabis allergy (IWT)
THANKS FOR YOUR ATTENTION